DMAA

Analyst Note: DMAA (Drugs Made In America Acquisition Corp.)

Date: 2026-06-13 Current Price: $10.60

1. Structural Readiness

• State: Context-only.
• Conservative Entry: Not yet actionable. Requires a confirmed close above the immediate consolidation high (breakout level).
• Aggressive/Pre-breakout Entry: Not recommended for standard setups; requires specific risk tolerance for SPAC arbitrage mechanics.
• Breakout Level: Unconfirmed. Requires price action to establish a new high above the current $10.60 consolidation range.
• Current Price: $10.60.
• Extension: None (Price is trading near the support floor, not extended).
• ATR Context: Current ATR is 0.2% (sub-threshold). This indicates extremely low volatility, typical of SPACs trading near trust value while awaiting a catalyst. The ATR at breakout is currently unmeasurable as no breakout has occurred.

2. Thesis Layer

• Thesis Classification: TACTICAL / Setup-Led.
• Macro Thesis: There is no named secular thesis attached to this name as of 2026-06-13. The investment case is not driven by a broad macro theme (e.g., "AI Revolution" or "Biotech Super-cycle") but is strictly dependent on the execution of the SPAC's business combination mandate.

3. Business Fundamentals

• Entity Type: Drugs Made In America Acquisition Corp. is a blank check company incorporated in the Cayman Islands on May 23, 2024.
• Business Model: The company has no operating revenues and does not expect to generate any until after the completion of an initial business combination (Evidence E14). Its sole purpose is to effect a merger, share exchange, or asset acquisition with one or more operating businesses (Evidence E4, E13).
• Financial Position (as of March 31, 2026):
• Trust Account: Held $242,020,416 in money market funds investing in U.S. Treasury securities (Evidence E5).
• Share Count: 24,276,913 ordinary shares outstanding following a redemption event on April 27, 2026 (Evidence E3).
• Trust Value Per Share: Approximately $10.52 per share (Evidence E3).
• Liquidity: The company has secured an interim convertible note of $100,000 from BV Advisory Partners, LLC, with a contemplated total financing of $500,000 (Evidence E6, E10, E11).
• Target Opportunity: Management has identified a potential business combination opportunity involving an enterprise technology platform focused on artificial intelligence, machine learning, quantum analytics, and cybersecurity, consistent with the business of Power Analytics Global Corporation (Evidence E12).
• Management: Saleem Elmasri serves as Chief Financial Officer, engaged via a master services agreement with Titan Advisory Services LLC (Evidence E7).

4. Archetype and Conviction

• Archetype: Structurally Broken / Waiting for Catalyst.
• *Reasoning:* As a pre-combination SPAC, the entity is structurally "broken" in the sense that it has no operations, no revenue, and no cash flow. It exists purely as a vehicle for a future transaction. It does not fit the "Quality Compounder" or "Growth Leader" archetypes until a target is acquired.
• Valuation Context: The stock is trading at $10.60, slightly above the trust value of $10.52. This minimal premium suggests the market is pricing in a high probability of a successful deal but is not yet pricing in a significant "deal premium" or "synergy" expectation.
• Conviction Stack:
• Thesis Strength: Low (No macro thesis, purely tactical).
• Evidence Quality: High (Clear SEC filings regarding trust value, redemption mechanics, and target identification).
• Rerating Potential: Binary. The stock will only rerate significantly upon the announcement or closing of a definitive business combination.
• ATR Analysis: The current ATR of 0.2% is sub-threshold (<2.5%), indicating a lack of volatility and a "sleeping" setup. This is typical for SPACs near the trust floor but suggests low immediate momentum.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• A closing price below $10.52 (the pro-rata trust value). This would signal a loss of confidence in the trust floor or a failure to secure the necessary financing to complete a deal before the deadline.
• Failure to complete a business combination by July 29, 2027 (15 months from the April 29, 2026 IPO closing, per Evidence E2).
• What Would Strengthen:
• A confirmed breakout above the current consolidation range (e.g., a close above $10.75-$10.80) accompanied by volume.
• Announcement of a definitive agreement for the Power Analytics Global Corporation transaction.
• Completion of the full $500,000 financing tranche beyond the initial $100,000 note.
• Gaps in Evidence:
• Target Financials: No financial data is provided for the potential target (Power Analytics Global Corporation). The quality of the asset is unknown.
• Deal Terms: No details on the valuation, dilution, or lock-up periods for the proposed transaction.
• Sponsor Commitment: While an interim loan exists, the extent of the sponsor's skin in the game beyond the $500k is not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key risks: No operating revenue or cash flow; Binary outcome dependent on single deal completion; Low volatility (sub-threshold ATR) suggests lack of momentum; Potential for trust liquidation if deal fails. Sizing hint: Position size should be minimal, reflecting the binary nature and lack of confirmed catalyst. Expected path: Management expects to close a deal with Power Analytics Global Corporation; price likely to remain range-bound near trust value until definitive agreement is announced. Expected horizon: 3 to 9 months (aligned with the 15-month deadline window). Failure mode to watch: A sustained close below $10.52, indicating a breakdown of the trust floor support.